Biopharma R&D Growing Stronger
The Bio Report
Biopharma Industry: Patent Expirations and Trial Trends
Exploring the impact of upcoming patent expirations on R&D investments and M&A activity in the biopharma sector. Delving into the significant decline in clinical trial starts in 2023, dissecting the reasons behind the decrease and the continued focus on rare disease trials. Highlighting the surge in GLP1 drug trials for obesity treatment, the rise in cell and gene therapy trials, and the decline in depression trial starts despite growing interest in mental health and psychedelics.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
